Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab

Table 5 Agreement (kappa coefficient) between ultrasonography (US) and magnetic resonance imaging (MRI) at baseline

US/MRI	Bursitis^a	Effusion/synovitis^b	Bursitis^a	Effusion/synovitis^b
Right hip	0.03 (–0.04; 0.11)	0.31 (–0.002; 0.62)	0.12 (–0.05; 0.29)	0.29 (–0.21; 0.78)
Left hip	0	0.16 (–0.22; 0.54)	0.03 (–0.04; 0.11)	0.09 (–0.37; 0.55)
Right shoulder	0.28 (–0.04; 0.11)	0.20 (–0.05; 0.45)	0.19 (–0.23; 0.61)	0.51 (0.04; 0.99)
Left shoulder	–0.08 (–0.52; 0.37)	0.20 (–0.05; 0.45)	–0.40 (–0.74; –0.06)	0.70 (0.32; 1)
Both hips	0.02 (–0.02; 0.05)	0.23 (–0.01; 0.42)	0.07 (–0.01; 0.16)	0.18 (–0.16; 0.52)
Both shoulders	0.11 (–0.16; 0.38)	0.20 (0.02; 0.37)	–0.14 (–0.50; 0.22)	0.61 (0.30; 0.91)
Four joints	0.02 (–0.01; 0.15)	0.21 (0.06; 0.37)	–0.07 (–0.28; 0.13)	0.38 (0.15; 0.62)

Two left-hand columns: MRI and US abnormalities defined as a score ≥ 1. Two right-hand columns: MRI abnormalities defined as a score ≥ 2 and US abnormalities as a score ≥ 1
^aBursitis: subacromial bursitis at the shoulders and trochanteric and iliopsoas bursitis at the hips
^bShoulders: glenohumeral joint and long head of biceps; hips: coxofemoral joints

ISSN: 1478-6362